184 related articles for article (PubMed ID: 19292734)
1. HER-2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study.
Rossi E; Grisanti S; Villanacci V; Della Casa D; Cengia P; Missale G; Minelli L; Buglione M; Cestari R; Bassotti G
J Cell Mol Med; 2009 Sep; 13(9B):3826-33. PubMed ID: 19292734
[TBL] [Abstract][Full Text] [Related]
2. TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma.
Rossi E; Villanacci V; Bassotti G; Donato F; Festa A; Cengia G; Grisanti S; Cestari R
Histopathology; 2010 Jul; 57(1):81-9. PubMed ID: 20557373
[TBL] [Abstract][Full Text] [Related]
3. Her-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
Walch A; Specht K; Bink K; Zitzelsberger H; Braselmann H; Bauer M; Aubele M; Stein H; Siewert JR; Höfler H; Werner M
Lab Invest; 2001 Jun; 81(6):791-801. PubMed ID: 11406641
[TBL] [Abstract][Full Text] [Related]
4. Early HER2 dysregulation in gastric and oesophageal carcinogenesis.
Fassan M; Mastracci L; Grillo F; Zagonel V; Bruno S; Battaglia G; Pitto F; Nitti D; Celiento T; Zaninotto G; Fiocca R; Rugge M
Histopathology; 2012 Nov; 61(5):769-76. PubMed ID: 22882541
[TBL] [Abstract][Full Text] [Related]
5. Amplification of Her-2/neu oncogene in GERD - Barrett's metaplasia – dysplasia - adenocarcinoma sequence.
Mokrowiecka A; Wierzchniewska-Lawska A; Smolarz B; Romanowicz-Makowska H; Lochowski M; Kozak J; Malecka-Panas E
Hepatogastroenterology; 2013; 60(125):1063-6. PubMed ID: 23591735
[TBL] [Abstract][Full Text] [Related]
6. GATA6 expression in Barrett's oesophagus and oesophageal adenocarcinoma.
Pavlov K; Honing J; Meijer C; Boersma-van Ek W; Peters FT; van den Berg A; Karrenbeld A; Plukker JT; Kruyt FA; Kleibeuker JH
Dig Liver Dis; 2015 Jan; 47(1):73-80. PubMed ID: 25445407
[TBL] [Abstract][Full Text] [Related]
7. HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.
Hu Y; Bandla S; Godfrey TE; Tan D; Luketich JD; Pennathur A; Qiu X; Hicks DG; Peters JH; Zhou Z
Mod Pathol; 2011 Jul; 24(7):899-907. PubMed ID: 21460800
[TBL] [Abstract][Full Text] [Related]
8. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus.
Kastelein F; Biermann K; Steyerberg EW; Verheij J; Kalisvaart M; Looijenga LH; Stoop HA; Walter L; Kuipers EJ; Spaander MC; Bruno MJ;
Gut; 2013 Dec; 62(12):1676-83. PubMed ID: 23256952
[TBL] [Abstract][Full Text] [Related]
9. HER2 expression in oesophageal carcinoma and Barrett's oesophagus associated adenocarcinoma: An Australian study.
Nagaraja V; Shaw N; Morey AL; Cox MR; Eslick GD
Eur J Surg Oncol; 2016 Jan; 42(1):140-8. PubMed ID: 26422587
[TBL] [Abstract][Full Text] [Related]
10. Reduced expression of αGlcNAc in Barrett's oesophagus adjacent to Barrett's adenocarcinoma--a possible biomarker to predict the malignant potential of Barrett's oesophagus.
Iwaya Y; Hasebe O; Koide N; Kitahara K; Suga T; Shinji A; Muraki T; Yokosawa S; Yamada S; Arakura N; Tanaka E; Nakayama J
Histopathology; 2014 Mar; 64(4):536-46. PubMed ID: 24117499
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy with trastuzumab in dysplasia and adenocarcinoma arising in Barrett's esophagus: a translational approach.
Villanacci V; Rossi E; Grisanti S; Bassotti G; Ferrari VD; Missale G; Minelli L; Cengia P; Marini G; Cestari R
Minerva Gastroenterol Dietol; 2008 Dec; 54(4):347-53. PubMed ID: 19047975
[TBL] [Abstract][Full Text] [Related]
12. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma.
Brien TP; Odze RD; Sheehan CE; McKenna BJ; Ross JS
Hum Pathol; 2000 Jan; 31(1):35-9. PubMed ID: 10665910
[TBL] [Abstract][Full Text] [Related]
13. p53 expression in Barrett's oesophagus, dysplasia, and adenocarcinoma using antibody DO-7.
Symmans PJ; Linehan JM; Brito MJ; Filipe MI
J Pathol; 1994 Jul; 173(3):221-6. PubMed ID: 7931842
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic biomarkers in progression from non-dysplastic Barrett's oesophagus to oesophageal adenocarcinoma: a systematic review protocol.
Nieto T; Tomlinson CL; Dretzke J; Bayliss S; Dilworth M; Beggs AD; Tucker O
BMJ Open; 2016 Dec; 6(12):e013361. PubMed ID: 27927666
[TBL] [Abstract][Full Text] [Related]
15. Fluorescence in situ hybridization mapping of esophagectomy specimens from patients with Barrett's esophagus with high-grade dysplasia or adenocarcinoma.
Brankley SM; Fritcher EG; Smyrk TC; Keeney ME; Campion MB; Voss JS; Clayton AC; Wang KK; Lutzke LS; Kipp BR; Halling KC
Hum Pathol; 2012 Feb; 43(2):172-9. PubMed ID: 21820152
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical assessment of Survivin and Bcl3 expression as potential biomarkers for NF-κB activation in the Barrett metaplasia-dysplasia-adenocarcinoma sequence.
Puccio I; Khan S; Butt A; Graham D; Sehgal V; Patel D; Novelli M; Lovat LB; Rodriguez-Justo M; Hamoudi RA
Int J Exp Pathol; 2018 Feb; 99(1):10-14. PubMed ID: 29473241
[TBL] [Abstract][Full Text] [Related]
17. Expression of CD44 in premalignant and malignant Barrett's oesophagus.
Lagorce-Pages C; Paraf F; Dubois S; Belghiti J; Fléjou JF
Histopathology; 1998 Jan; 32(1):7-14. PubMed ID: 9522210
[TBL] [Abstract][Full Text] [Related]
18. Molecular evaluation of ablative therapy of Barrett's oesophagus.
Hage M; Siersema PD; Vissers KJ; Steyerberg EW; Haringsma J; Kuipers EJ; van Dekken H
J Pathol; 2005 Jan; 205(1):57-64. PubMed ID: 15586364
[TBL] [Abstract][Full Text] [Related]
19. Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel.
Duits LC; Phoa KN; Curvers WL; Ten Kate FJ; Meijer GA; Seldenrijk CA; Offerhaus GJ; Visser M; Meijer SL; Krishnadath KK; Tijssen JG; Mallant-Hent RC; Bergman JJ
Gut; 2015 May; 64(5):700-6. PubMed ID: 25034523
[TBL] [Abstract][Full Text] [Related]
20. Value of α-methylacyl-CoA racemase immunochemistry for predicting neoplastic progression in Barrett's oesophagus.
Kastelein F; Biermann K; Steyerberg EW; Verheij J; Kalisvaart M; Looijenga LH; Stoop HA; Walter L; Kuipers EJ; Spaander MC; Bruno MJ;
Histopathology; 2013 Nov; 63(5):630-9. PubMed ID: 24004067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
